PanGen Biotech Inc (222110) — Cash Flow-to-Debt Ratio
PanGen Biotech Inc (222110) has a Cash Flow-to-Debt Ratio of -1.34x as of September 2025, meaning its operating cash flow of ₩-3.66 Billion could theoretically repay -1% of its total liabilities (₩2.74 Billion) in one year. See PanGen Biotech Inc (222110) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
PanGen Biotech Inc Cash Flow-to-Debt Ratio (2014–2024)
Historical debt coverage capacity for PanGen Biotech Inc across 11 annual periods. Also explore PanGen Biotech Inc (222110) equity growth momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for PanGen Biotech Inc (2014–2024)
Year-by-year debt coverage analysis for PanGen Biotech Inc. For market capitalisation and broader financial context, see 222110 stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.53x | ₩2.99 Billion | ₩5.64 Billion | ▲ +225.6% |
| 2023 | -0.42x | ₩-3.45 Billion | ₩8.18 Billion | ▲ +58.4% |
| 2022 | -1.01x | ₩-3.50 Billion | ₩3.45 Billion | ▼ -576.6% |
| 2021 | -0.15x | ₩-3.32 Billion | ₩22.18 Billion | ▲ +29.2% |
| 2020 | -0.21x | ₩-4.68 Billion | ₩22.10 Billion | ▼ -19.5% |
| 2019 | -0.18x | ₩-3.66 Billion | ₩20.66 Billion | ▲ +41.0% |
| 2018 | -0.30x | ₩-5.61 Billion | ₩18.67 Billion | ▼ -95.7% |
| 2017 | -0.15x | ₩-657.84 Million | ₩4.28 Billion | ▲ +92.6% |
| 2016 | -2.08x | ₩-4.35 Billion | ₩2.09 Billion | ▼ -1107.5% |
| 2015 | -0.17x | ₩-1.61 Billion | ₩9.34 Billion | ▲ +20.6% |
| 2014 | -0.22x | ₩-1.34 Billion | ₩6.18 Billion | — |